Cannabinoid CB1 receptors are involved in motivational effects of nicotine in rats

Forget, Benoît; Hamon, Michel; Thiébot, Marie-Hélène

doi:10.1007/s00213-005-0015-6

Cited by 104 publications

(101 citation statements)

References 102 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In preclinical studies, the CB1 antagonist rimonabant reduces or blocks both the intravenous self-administration of nicotine and the development and expression of nicotine-induced conditioned place preferences in rats (170,173). Rimonabant also reduces the motivational impact of drug-related cues or environments on nicotine-seeking behavior (174)(175)(176).…”

Section: Nicotinementioning

confidence: 99%

Endocannabinoid system involvement in brain reward processes related to drug abuse

Solinas

Yaşar

Goldberg

2007

Pharmacological Research

View full text Add to dashboard Cite

Cannabis is the most commonly abused illegal drug in the world and its main psychoactive ingredient, delta-9-tetrahydrocannabinol (THC), produces rewarding effects in humans and non-human primates. Over the last several decades, an endogenous system comprised of cannabinoid receptors, endogenous ligands for these receptors and enzymes responsible for the synthesis and degradation of these endogenous cannabinoid ligands has been discovered and partly characterized. Experimental findings strongly suggest a major involvement of the endocannabinoid system in general brain reward functions and drug abuse. First, natural and synthetic cannabinoids and endocannabinoids can produce rewarding effects in humans and laboratory animals. Second, activation or blockade of the endogenous cannabinoid system has been shown to modulate the rewarding effects of noncannabinoid psychoactive drugs. Third, most abused drugs alter brain levels of endocannabinoids in the brain. In addition to reward functions, the endocannabinoid cannabinoid system appears to be involved in the ability of drugs and drug-related cues to reinstate drug-seeking behavior in animal models of relapse. Altogether, evidence points to the endocannadinoid system as a promising target for the development of medications for the treatment of drug abuse.

show abstract

Section: Nicotinementioning

confidence: 99%

Endocannabinoid system involvement in brain reward processes related to drug abuse

Solinas

Yaşar

Goldberg

2007

Pharmacological Research

View full text Add to dashboard Cite

show abstract

“…One week before the beginning of the experiments, all the animals were foodrestricted (20 g/day) until the end of the study. This was carried out because food restriction has been reported to enhance the rewarding effects of drugs of abuse (Carr 2002), including nicotine (Donny et al, 1998), and the study on which our protocol is based uses a foodrestriction regimen (Forget et al, 2005). Experiments were subject to institutional review and conducted in accordance with the Veterinary Authority of Basel-Stadt (Basel, Switzerland).…”

Section: Methodsmentioning

confidence: 99%

GABA_B Receptor-Positive Modulation-Induced Blockade of the Rewarding Properties of Nicotine Is Associated with a Reduction in Nucleus Accumbens ΔFosB Accumulation

Mombereau¹,

Lhuillier²,

Kaupmann³

et al. 2007

J Pharmacol Exp Ther

View full text Add to dashboard Cite

There is an increasing demand for a novel non-nicotinic, nondopaminergic therapeutic approach to nicotine addiction. GABAergic mechanisms have been implicated in drug dependence. Recently, a novel GABA B receptor allosteric-positive modulator, GS39783, was characterized. There are no investigations to date on the effects of GABA B receptor-positive modulators in animal models of nicotine reinforcement. Conditioned place preference (CPP) paradigms are based on the principle that animals, like humans, would learn to seek environmental stimuli that have been previously associated with rewarding events. Here we show that nicotine (0.06 mg/kg s.c.) induced a robust CPP response. Furthermore, GS39783 (30 -100 mg/kg p.o.) during the conditioning phase blocked the rewarding effects of nicotine in the CPP paradigm in rats. However, GS39783 did not significantly alter the CPP effects of nicotine when given only immediately before the CPP test. A growing body of evidence suggests that repeated administration of drugs of abuse induced long-term molecular changes in brain plasticity, most notably an accumulation of ⌬FosB, in the striatal complex that contribute to the manifestation of dependence. There was a significant accumulation of ⌬FosB in the nucleus accumbens, but not in the dorsal striatum, of rats treated daily for 5 days with nicotine (0.06 mg/kg i.p.). GS39783 completely (30 -100 mg/kg p.o.) counteracted these nicotineinduced molecular adaptations when given before the CPP acquisition phase but not when administered immediately before the test phase. Taken together, the behavioral and molecular changes induced by nicotine occur in concert and are concomitantly amenable to reversal by GABA B receptor-positive modulators.

show abstract

“…Briefly, rimonabant has been found to decrease nicotine self-administration (Cohen et al 2002;Kodas et al 2007), cue-induced reinstatement of nicotine seeking (Cohen et al 2004;De Vries et al 2005), and nicotine-conditioned place preferences (Forget et al 2005;Le Foll and Goldberg 2004). The operant discriminative stimulus (S D ) effects of nicotine do not appear to be affected by pretreatment with rimonabant (Cohen et al 2002;Le Foll and Goldberg 2004;Zaniewska et al 2006).…”

Section: Introductionmentioning

confidence: 99%

Investigation of endocannabinoid modulation of conditioned responding evoked by a nicotine CS and the Pavlovian stimulus effects of CP 55,940 in adult male rats

et al. 2009

View full text Add to dashboard Cite

Rationale -The cannabinoid CB 1 receptor antagonist/inverse agonist rimonabant (SR 141716) has been shown to block reinforcing and rewarding effects of nicotine. Research has not investigated whether the cannabinoid system is involved in the interoceptive stimulus effects of nicotine functioning as a conditional stimulus (CS). Objective -We examined the effects of rimonabant and the CB 1/2 receptor agonist, CP 55,940, on responding evoked by a nicotine CS in rats. Additionally, we determined whether CP 55,940 functioned as a CS or a Pavlovian positive drug feature Materials and methods -Pavlovian discrimination training involved intermixed nicotine (0.2 mg base/kg) and saline sessions with intermittent access to water only on nicotine. Antagonism tests with rimonabant (0.1-3 mg/kg) and substitution tests with CP 55,940 (0.003-0.1 mg/kg) followed. An effective dose of CP 55,940 was tested against the nicotine generalization curve. A separate group received CS training with CP 55,940 (0.01 mg/kg). Two other groups were trained using CP 55,940 (0.01 or 0.03 mg/kg) as a positive drug feature in which a brief light CS signaled access to water only on CP 55,940 sessions Results -Rimonabant blocked nicotine-evoked responding.CP 55,940 partially substituted for nicotine and enhanced responding to lower nicotine doses. Overall, CP 55,940 did not acquire control of conditioned responding in either Pavlovian drug discrimination task Conclusions -The cannabinoid system was involved in the CS effects of nicotine. This finding is counter to the operant drug discrimination research with nicotine as a discriminative stimulus, warranting further research into this possible dissociation.

show abstract

Cannabinoid CB1 receptors are involved in motivational effects of nicotine in rats

Cited by 104 publications

References 102 publications

Endocannabinoid system involvement in brain reward processes related to drug abuse

Endocannabinoid system involvement in brain reward processes related to drug abuse

GABA_B Receptor-Positive Modulation-Induced Blockade of the Rewarding Properties of Nicotine Is Associated with a Reduction in Nucleus Accumbens ΔFosB Accumulation

Investigation of endocannabinoid modulation of conditioned responding evoked by a nicotine CS and the Pavlovian stimulus effects of CP 55,940 in adult male rats

Contact Info

Product

Resources

About

Cannabinoid CB1 receptors are involved in motivational effects of nicotine in rats

Cited by 104 publications

References 102 publications

Endocannabinoid system involvement in brain reward processes related to drug abuse

Endocannabinoid system involvement in brain reward processes related to drug abuse

GABAB Receptor-Positive Modulation-Induced Blockade of the Rewarding Properties of Nicotine Is Associated with a Reduction in Nucleus Accumbens ΔFosB Accumulation

Investigation of endocannabinoid modulation of conditioned responding evoked by a nicotine CS and the Pavlovian stimulus effects of CP 55,940 in adult male rats

Contact Info

Product

Resources

About

GABA_B Receptor-Positive Modulation-Induced Blockade of the Rewarding Properties of Nicotine Is Associated with a Reduction in Nucleus Accumbens ΔFosB Accumulation